Your session is about to expire
← Back to Search
VP-001 for Retinal Dystrophy (Platypus Trial)
Platypus Trial Summary
This trial tests a drug to see if it can safely help people with a genetic eye condition called retinal dystrophy.
Platypus Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Platypus Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have cloudiness or poor dilation in my eye's pupil.I have recently used anti-VEGF treatments or had corticosteroid injections or implants.My eye condition is not RP11.I have a genetic mutation in PRPF31.I do not have any uncontrolled illnesses that would stop me from joining the study.My retinal disease is due to specific genetic mutations, not including PRPF31.I have had recent eye surgery.I am 18 years old or older.I have not used any experimental drugs or devices recently.I am not pregnant or breastfeeding and will not become pregnant or father a child during the study.I have RP11-related eye disease but my macular edema is stable.I have PRPF31-related eye disease with stable swelling in my macula, if any.I have had cell or gene therapy for an eye condition before.
- Group 1: Single arm dose escalation study of VP-001
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any remaining opportunities to participate in this trial?
"Affirmative. The clinical trial is actively registering patients in accordance with the information hosted on clinicaltrials.gov, which was first published on April 20th of 2023 and most recently modified on June 5th of that same year. For this research endeavour, only 20 participants are needed from a single recruitment site."
Is there any evidence to suggest that Single arm dose escalation study of VP-001 may be detrimental for individuals?
"Single arm dose escalation study of VP-001 has limited data to support its efficacy and safety, thus receiving a rating of 1 on our scale."
How many people can take part in this trial at its peak?
"Yes, the data posted on clinicaltrials.gov certifies that this medical experiment is in progress and recruiting patients. This research was first announced on April 20th of 2023 and has been recently revised as of June 5th, 2023; they are currently looking for a total of twenty participants from one location."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger